Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Iqvia Holdings Inc (IQV): Why RiverPark Loves This Health Care Services Company

RiverPark is bullish on Iqvia Holdings Inc (NYSE:IQV) in which the fund started a new position during the fourth quarter of 2017. In its Long/Short Opportunity Fund Q4 Investor Letter, RiverPark discussed its investment thesis on Iqvia Holdings Inc (IQV). Let’s take a look at the fund’s thoughts on the $21-billion market cap provider of integrated information and technology-enabled healthcare services.

IQVIA Holdings was created from the October 2016 merger of Quintiles, a premier contract research organization (CRO) to pharmaceutical and biotechnology companies, and IMS, a best-in-class information and technology service firm to the same customers. While the merger is expected to provide cost synergies across the $8.5 billion combined company, more importantly, it should enhance the revenue growth rate for its CRO division, as it integrates IMS’s data and analytical tools into its offerings. We believe that the market opportunity for pharmaceutical and biotechnology R&D is rapidly growing as the number of drug candidates in the various pipelines is at record levels, driven by a growing and aging global population, flush capital markets, active venture capital and healthcare research funding and improving global economies. This has led to a steadily improving outlook for CROs as clients are increasingly outsourcing their research and development to third parties.

The new company aims to create a “smarter” CRO that can take substantial market share in this growing industry by combining IMS’s historical data and analytical tools – IMS’ data covers 85% of the world’s prescription sales and includes information on more than 500 million patients – with Quintiles leading clinical trials service –the company is the world’s largest provider of biopharmaceutical development services. In fact, in just the few months since the merger, the company has already won business based on its next generation approach, which bodes well for accelerating revenue growth for the combined company. IQV is expected to generate mid-to-high single digit revenue growth that we believe will be combined with disciplined expense management and strong operating leverage and should lead to double-digit EPS growth. With 25% EBITDA margins and low capital intensity, the company should also generate strong growth in free cash flow, in excess of $1 billion per year, providing additional earnings leverage from capital deployment and/or share buybacks.

Although IQV shares have had a strong run since the merger, the stock pulled back after the company’s analyst day during the fourth quarter when some investors were disappointed in management’s near-term revenue guidance (which we perceived as conservative), giving us the opportunity to initiate a small position in this leading health care services company.

ESB Professional/

ESB Professional/

Iqvia Holdings Inc (NYSE:IQV) provides information, technology solutions and contract research services to the healthcare industry. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 55,000 employees in more than 100 countries.

For the fourth quarter ended December 31, IQVIA reported revenue of $2.16 billion, up 10.7% on a reported basis, and 8.4% on a constant currency basis, compared to the same quarter of 2016. The company had net income of $1.08 billion, or $5.02 earnings per share, versus a loss of $178 million, or $0.74 per share, for the same 2016’s quarter. For the full-year 2017, revenue was $8.06 billion, up 4.3% reported and 4.2% on a constant currency basis, compared to the combined company results in 2016. For the full year of 2017, net income was $1.31 billion, or $5.88 per share, compared to $115 million and $0.76 per share, for 2016.

Meanwhile, shares of Iqvia Holdings Inc (NYSE:IQV) are up 3.9% so far this year. The stock was closed up 0.16% at $101.72 on Friday. It has gained nearly 2% over the past 30 days.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.